GILD · earnings call history
Gilead Q1 FY26 — Strong Commercial Performance and Increased Guidance
Read the briefGilead Q4 FY25 — Strong HIV and Livdelzi Performance Drives Sales Beat, Robust 2026 Launch Pipeline
Read the briefGilead Q3 FY25 — Strong HIV and Livdelzi Performance Drives Raised Full-Year Outlook
Read the briefGilead Q4 FY24 — Strong Base Business Growth and Pipeline Advancement
Read the briefBrowse all US companies on the earnings-call register.